Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- MRKR
- Price
- 2.04
- Stock movement down
- -0.15 (-6.85%)
- Company name
- Marker Therapeutics Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 26.40M
- Ent value
- 12.15M
- Price/Sales
- 5.62
- Price/Book
- 1.44
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -23.96%
- 1 year return (CAGR)
- -0.49%
- 3 year return (CAGR)
- -
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2026-01-22
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
MRKR does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 5.62 |
| Price to Book | 1.44 |
| EV to Sales | 2.59 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 12.94M |
| EPS (TTM) | -0.85 |
| FCF per share (TTM) | -0.88 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 4.69M |
| Gross profit (TTM) | -7.70M |
| Operating income (TTM) | -14.87M |
| Net income (TTM) | -14.30M |
| EPS (TTM) | -0.85 |
| EPS (1y forward) | -0.79 |
Margins
Loading...
Margins data
| Gross margin (TTM) | -164.08% |
| Operating margin (TTM) | -316.67% |
| Profit margin (TTM) | -304.54% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 17.59M |
| Net receivables | 1.67M |
| Total current assets | 21.73M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 21.73M |
| Accounts payable | 951.00K |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 3.35M |
| Total liabilities | 3.35M |
| Shareholder's equity | 18.39M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -14.82M |
| Capital expenditures (TTM) | 12.00 |
| Free cash flow (TTM) | -14.82M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -77.75% |
| Return on Assets | -65.78% |
| Return on Invested Capital | -77.75% |
| Cash Return on Invested Capital | -80.58% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 2.23 |
| Daily high | 2.29 |
| Daily low | 1.93 |
| Daily Volume | 861K |
| All-time high | 778.80 |
| 1y analyst estimate | 7.33 |
| Beta | 1.35 |
| EPS (TTM) | -0.85 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| MRKR | S&P500 | |
| Current price drop from All-time high | -99.74% | -0.89% |
| Highest price drop | -99.89% | -19.00% |
| Date of highest drop | 9 Sep 2025 | 8 Apr 2025 |
| Avg drop from high | -99.77% | -2.49% |
| Avg time to new high | - | 6 days |
| Max time to new high | 322 days | 89 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
26.40M
Marketcap category
Small-cap
Description
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia AND myelodysplastic syndromes; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.
Employees
5
Investor relations
-
SEC filings
CEO
Peter L. Hoang
Country
USA
City
Houston
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page